"japippy" aka Jim Petersen is a drug addict from
peoria AZ. He is about to die from old age,
but still hassles people on-line
very very sad man, this Jim Petersen from Peoria AZ
... more »
It’s been a long time, I have covered this company since 1997 when it was nothing quite more than a vision in the mind of its incubators. What a challenge I thought. This small idea has grown into an immensely successful company and I still marvel at its achievements. I speak of Falken Industries L...
... more »
CAVR
+ 5.26% after the close on the up tick
RSI LINE @56.43 and on and upward trend
Yesterdays volume was 159,788
its above all the resistence levels
theres a lot of chatter about CAVR
i believe its going to have another big day
watch it
... more »
People are losing faith, adverse consequences are soon about to reveal themselves.
Throughout the world there is 134T of bonds, including corporate and government debt, though currently above ground there is not even 5T in Gold, I think investors all throughout the world are losing their patience ...
... more »
HOPE OR HOPELESS!
REALITY IS SHAREHOLDERS DIDN'T WANT TO HEAR IT. NOT ONLY DID I STATE ON THIS SITE AND MANY OTHERS, THAT THE STOCK WAS GOING BACK UNDER $1 DOLLAR, BUT THE COMPANY ONCE AGAIN HAS TO SEEK FUNDING FOR 2010 EXPENSES YET. I MEAN PRE-CLINICAL STAGE COMPANY, NO SERIOUS EARNINGS REVENUE AN...
... more »
CytRx to Initiate Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Gastric Cancer
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a ...
... more »
StemCells, Inc. Provides Update on NCL Program Meeting with FDA
StemCells, Inc. (NASDAQ: STEM) today provided an update on the ongoing clinical development program of its proprietary HuCNS-SC® product candidate (purified human neural stem cells) for neuronal ceroid lipofuscinosis (NCL),...
... more »
CAVU’s business strategy will be growth through developing proven leases utilizing its core business assets in drilling as well as servicing (reworking and re-conditioning) existing production. The Company’s current area of focus includes Colorado, Kansas, Louisiana, Montana, Oklahoma and Texas.
...
... more »
BUT WITH THESE SIGNALS YOU MAY WANT TO GET A HEAD START NOW. MRNA -BARCHART 96% SELL
INO.TREND ANALYSIS: MRNA scored -100 on a scale from -100 (strong downtrend) to +100 (strong uptrend)
-10 Last Hour Close Below 5 hour Moving Average
-15 New 3 Day Low on Friday
-20 Last Price Below 20 Day Mov...
... more »
Amedisys Inc (AMED), a provider of home health care and hospice services, posted second-quarter results that beat market estimates and said its integration of TLC Health Care Services was ahead of schedule.
Net service revenue rose about 85 percent to $312.7 million.
As I have written before I simply...
... more »
EXPU UPDATED DD POST
Expert Group’s primary revenue engine is “Expert Financing.” This company specializes in providing residential and commercial loans and has been in business since 2005 in the Florida marketplace.
Recently, Expert Financing has experienced a notable surge of growth, sh...
... more »
"COMPANY SURPRESSING GOOD NEWS, MRNA IS GOING TO TAKE OFF." THIS IS THE GARBAGE POSTED TODAY ON THE MESSAGE BOARD.
AND POSTED BY GOATSHEAD, A NAME YOU KNOW & TRUST!
IF THERE WAS NEWS IT MUST BE DISCLOSED.
SEC REGULATIONS.
LASTLY, THIS STOCK WILL CONTINUE TO GO LOWER, AND LOWER, UNLESS SOME IGNOR...
... more »
Dear Friends:
SNBP is our New Pick www.sinobiopharma.com
SINO BIOPHARMA SNBP a Fully integrated specality biopharmaceutical company with 30,000 sq.meter Certified Production Facilities in China.
Estimated Chinese Health Care Market Demand of $600 Billion by 2015.We all are aware China’s...
... more »
TODAYS ARTICLE-STOCKPERSPECTIVE-STOCKSCORES, (SOUND ALL TOO FAMILIAR)
"The best traders are not afraid of holding on to strong stocks, they are afraid of holding on to losing stocks. What do you do?
If you are a normal human being, you do the opposite. Think about the last loser that you owned. ...
... more »
Business is tough, I see it everywhere in the market place, but the more I meander within the industry the more I return, at great risk of more badgering from my critic, to the fundamentals – strong research and development, leadership in product conceptions, broad distribution including platforms ...
... more »
Ventana Biotech has filed
GB200910102 claiming chewing gum
compositions comprising 2-hydroxyoleic
acid and extracts of Hoodia gordonii
with appetite suppressant activity. The
application also names Anders Jenson as
co-assignee. On July 28, 2009, the day
before the UK Intellectual Property Offi...
... more »
Ventana Biotech (VNTA) is rocking the anti-obesity segment of the health care industry with news of a chewing gum that releases targeted hormonal triggers into the body with each chew. You feel full, even when you're not.
Royalty cash flow from an anti-obesity drug is estimated at $1.5 to $1.7 bill...
... more »
hello, there is now pretty strong evidence, although all people are considered innocent until all facts are in, that Japippy@aol.com is a meth addict and
sever boozer. He gets wasted all day and jerks around the various discussiuon boards.
Many refer to him as
-blowhard
-queer
-dis honest
-b...
... more »
If you're interested in learning more about trading options, drop by this website, http://www.safe-options-trading-income.com/. This is an informational and educational website devoted to learning how to make extra income using safe, conservative options-selling techniques. Topics covered include cov...
... more »
Data powered by FinancialContent.
All Rights Reserved.
Quotes delayed at least 20 minutes unless otherwise indicated.
None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.